IMG 1010
IMG 1010
2 Sep

High Priority Recommendation for Widening Access to Kalydeco

2 September 2022

Positive news from the Respiratory Advisory Committee recommending high priority for the expansion of access to Kalydeco. 

In August 2021, a member of our CF community made a “consumer” application to Pharmac to have the criteria for access to Vertex’s CFTR modulator Kalydeco, widened. The application sought approval for additional mutations to be added to Pharmac’s existing access criteria for Kalydeco.

This application was considered by Pharmac’s Respiratory Advisory Committee at its April meeting, alongside Trikafta.

Today Pharmac has published the full record of that meeting – which can be read here.

CFNZ is delighted that Pharmac’s expert advisors have recommended a high priority for expanding access to Kalydeco. But like Trikafta, there has now been enough assessment, reassessment and review – Pharmac already funds Kalydeco so knows how effective it is.

It’s time for action and decisions. Everyone in New Zealand needs access to a CFTR modulator therapy that works for them, and they need it now. Our people with CF don’t have time to wait.

CFNZ urges Pharmac and Vertex to come to an agreement for both Trikafta and the widening of access to Kalydeco as soon as possible.

Thank you again to the consumer who made the application.